U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Tyrosine kinase inhibitor response

MedGen UID:
830645
•Concept ID:
CN225347
•
Sign or Symptom
Synonym: Protein-tyrosine kinase inhibitor response
Drug:
Tyrosine kinase inhibitor
MedGen UID:
266120
•Concept ID:
C1268567
•
Pharmacologic Substance
Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation. [from NCI]
Tyrosine kinase inhibitor

Professional guidelines

PubMed

Treatment Landscape of Renal Cell Carcinoma.
Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR
Curr Treat Options Oncol 2023 Dec;24(12):1889-1916. Epub 2023 Dec 28 doi: 10.1007/s11864-023-01161-5. PMID: 38153686Free PMC Article
Diagnosis, course and management of hypersensitivity pneumonitis.
Hamblin M, Prosch H, Vašáková M
Eur Respir Rev 2022 Mar 31;31(163) Epub 2022 Feb 9 doi: 10.1183/16000617.0169-2021. PMID: 35140104Free PMC Article
New Treatment Addressing the Pathogenesis of Psoriasis.
Tokuyama M, Mabuchi T
Int J Mol Sci 2020 Oct 11;21(20) doi: 10.3390/ijms21207488. PMID: 33050592Free PMC Article

Recent clinical studies

Etiology

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
van Outersterp I, Tasian SK, Reichert CEJ, Boeree A, de Groot-Kruseman HA, Escherich G, Boer JM, den Boer ML
Blood 2024 May 23;143(21):2178-2189. doi: 10.1182/blood.2023023120. PMID: 38394665Free PMC Article
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Pokorny R, Stenehjem DD, Gilreath JA
J Oncol Pharm Pract 2022 Jun;28(4):916-923. Epub 2022 Feb 8 doi: 10.1177/10781552221077254. PMID: 35132891Free PMC Article
Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A, Vasudevan S
Cancer Treat Res Commun 2021;28:100398. Epub 2021 May 13 doi: 10.1016/j.ctarc.2021.100398. PMID: 34052672
Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J, Wang L, Ng NN, Zhao M, Shi J, Wu N, Li W, Liu Z, Yeom KW, Tian J
JAMA Netw Open 2020 Dec 1;3(12):e2030442. doi: 10.1001/jamanetworkopen.2020.30442. PMID: 33331920Free PMC Article
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.
Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A, Bex A, Powles T, Gerlinger M
BMC Med 2016 Nov 14;14(1):185. doi: 10.1186/s12916-016-0729-9. PMID: 27842541Free PMC Article

Diagnosis

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction.
Latini S, Venafra V, Massacci G, Bica V, Graziosi S, Pugliese GM, Iannuccelli M, Frioni F, Minnella G, Marra JD, Chiusolo P, Pepe G, Helmer Citterich M, Mougiakakos D, Böttcher M, Fischer T, Perfetto L, Sacco F
Elife 2024 Apr 2;12 doi: 10.7554/eLife.90532. PMID: 38564252Free PMC Article
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
van Outersterp I, Tasian SK, Reichert CEJ, Boeree A, de Groot-Kruseman HA, Escherich G, Boer JM, den Boer ML
Blood 2024 May 23;143(21):2178-2189. doi: 10.1182/blood.2023023120. PMID: 38394665Free PMC Article
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Pokorny R, Stenehjem DD, Gilreath JA
J Oncol Pharm Pract 2022 Jun;28(4):916-923. Epub 2022 Feb 8 doi: 10.1177/10781552221077254. PMID: 35132891Free PMC Article
Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J, Wang L, Ng NN, Zhao M, Shi J, Wu N, Li W, Liu Z, Yeom KW, Tian J
JAMA Netw Open 2020 Dec 1;3(12):e2030442. doi: 10.1001/jamanetworkopen.2020.30442. PMID: 33331920Free PMC Article
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC
J Clin Oncol 2012 Feb 1;30(4):433-40. Epub 2012 Jan 3 doi: 10.1200/JCO.2011.38.3224. PMID: 22215752

Therapy

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
van Outersterp I, Tasian SK, Reichert CEJ, Boeree A, de Groot-Kruseman HA, Escherich G, Boer JM, den Boer ML
Blood 2024 May 23;143(21):2178-2189. doi: 10.1182/blood.2023023120. PMID: 38394665Free PMC Article
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Pokorny R, Stenehjem DD, Gilreath JA
J Oncol Pharm Pract 2022 Jun;28(4):916-923. Epub 2022 Feb 8 doi: 10.1177/10781552221077254. PMID: 35132891Free PMC Article
Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A, Vasudevan S
Cancer Treat Res Commun 2021;28:100398. Epub 2021 May 13 doi: 10.1016/j.ctarc.2021.100398. PMID: 34052672
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.
Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A, Bex A, Powles T, Gerlinger M
BMC Med 2016 Nov 14;14(1):185. doi: 10.1186/s12916-016-0729-9. PMID: 27842541Free PMC Article
Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S, Wu H, Wang J, Qiu Q
Mol Inform 2016 Oct;35(10):495-505. doi: 10.1002/minf.201600039. PMID: 27712045

Prognosis

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction.
Latini S, Venafra V, Massacci G, Bica V, Graziosi S, Pugliese GM, Iannuccelli M, Frioni F, Minnella G, Marra JD, Chiusolo P, Pepe G, Helmer Citterich M, Mougiakakos D, Böttcher M, Fischer T, Perfetto L, Sacco F
Elife 2024 Apr 2;12 doi: 10.7554/eLife.90532. PMID: 38564252Free PMC Article
Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A, Vasudevan S
Cancer Treat Res Commun 2021;28:100398. Epub 2021 May 13 doi: 10.1016/j.ctarc.2021.100398. PMID: 34052672
Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J, Wang L, Ng NN, Zhao M, Shi J, Wu N, Li W, Liu Z, Yeom KW, Tian J
JAMA Netw Open 2020 Dec 1;3(12):e2030442. doi: 10.1001/jamanetworkopen.2020.30442. PMID: 33331920Free PMC Article
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X
Clin Lung Cancer 2015 Sep;16(5):e25-35. Epub 2015 Feb 19 doi: 10.1016/j.cllc.2015.02.002. PMID: 25801750
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y, Ochiai A
J Cancer Res Clin Oncol 2013 Oct;139(10):1691-700. Epub 2013 Aug 22 doi: 10.1007/s00432-013-1495-0. PMID: 23974272

Clinical prediction guides

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction.
Latini S, Venafra V, Massacci G, Bica V, Graziosi S, Pugliese GM, Iannuccelli M, Frioni F, Minnella G, Marra JD, Chiusolo P, Pepe G, Helmer Citterich M, Mougiakakos D, Böttcher M, Fischer T, Perfetto L, Sacco F
Elife 2024 Apr 2;12 doi: 10.7554/eLife.90532. PMID: 38564252Free PMC Article
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
van Outersterp I, Tasian SK, Reichert CEJ, Boeree A, de Groot-Kruseman HA, Escherich G, Boer JM, den Boer ML
Blood 2024 May 23;143(21):2178-2189. doi: 10.1182/blood.2023023120. PMID: 38394665Free PMC Article
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Pokorny R, Stenehjem DD, Gilreath JA
J Oncol Pharm Pract 2022 Jun;28(4):916-923. Epub 2022 Feb 8 doi: 10.1177/10781552221077254. PMID: 35132891Free PMC Article
Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J, Wang L, Ng NN, Zhao M, Shi J, Wu N, Li W, Liu Z, Yeom KW, Tian J
JAMA Netw Open 2020 Dec 1;3(12):e2030442. doi: 10.1001/jamanetworkopen.2020.30442. PMID: 33331920Free PMC Article
Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S, Wu H, Wang J, Qiu Q
Mol Inform 2016 Oct;35(10):495-505. doi: 10.1002/minf.201600039. PMID: 27712045

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...